These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
307 related articles for article (PubMed ID: 29280138)
21. Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized Trials. Tota JE; Struyf F; Merikukka M; Gonzalez P; Kreimer AR; Bi D; Castellsagué X; de Carvalho NS; Garland SM; Harper DM; Karkada N; Peters K; Pope WAJ; Porras C; Quint W; Rodriguez AC; Schiffman M; Schussler J; Skinner SR; Teixeira JC; Wheeler CM; Herrero R; Hildesheim A; Lehtinen M; J Natl Cancer Inst; 2017 Jan; 109(7):. PubMed ID: 28132019 [TBL] [Abstract][Full Text] [Related]
22. HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives. Castellsagué X; Schneider A; Kaufmann AM; Bosch FX Gynecol Oncol; 2009 Dec; 115(3 Suppl):S15-23. PubMed ID: 19819540 [TBL] [Abstract][Full Text] [Related]
23. Evaluation of the interim analysis from the PATRICIA study group: efficacy of a vaccine against HPV 16 and 18. Frederick PJ; Huh WK; Expert Rev Anticancer Ther; 2008 May; 8(5):701-5. PubMed ID: 18471043 [TBL] [Abstract][Full Text] [Related]
24. Prevalence and type distribution of human papillomavirus in 5,000 British Columbia women--implications for vaccination. Moore RA; Ogilvie G; Fornika D; Moravan V; Brisson M; Amirabbasi-Beik M; Kollar A; Burgess T; Hsu R; Towers L; Lo J; Matisic J; Brooks-Wilson A Cancer Causes Control; 2009 Oct; 20(8):1387-96. PubMed ID: 19475481 [TBL] [Abstract][Full Text] [Related]
25. Baseline prevalence and type distribution of human papillomavirus in healthy Chinese women aged 18-25 years enrolled in a clinical trial. Zhao FH; Zhu FC; Chen W; Li J; Hu YM; Hong Y; Zhang YJ; Pan QJ; Zhu JH; Zhang X; Chen Y; Tang H; Zhang H; Durand C; Datta SK; Struyf F; Bi D; Int J Cancer; 2014 Dec; 135(11):2604-11. PubMed ID: 24740547 [TBL] [Abstract][Full Text] [Related]
29. Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing. Lehtinen M; Apter D; Dubin G; Kosunen E; Isaksson R; Korpivaara EL; Kyhä-Osterlund L; Lunnas T; Luostarinen T; Niemi L; Palmroth J; Petäjä T; Rekonen S; Salmivesi S; Siitari-Mattila M; Svartsjö S; Tuomivaara L; Vilkki M; Pukkala E; Paavonen J Int J STD AIDS; 2006 Aug; 17(8):517-21. PubMed ID: 16925896 [TBL] [Abstract][Full Text] [Related]
30. [Cervical carcinoma and the vaccination experience with Cervarix]. Berberova M Akush Ginekol (Sofiia); 2012; 51 Suppl 1():4-5. PubMed ID: 23236670 [No Abstract] [Full Text] [Related]
31. Cost-effectiveness analysis of the bivalent compared with the quadrivalent human papillomavirus vaccines in Taiwan. Demarteau N; Tang CH; Chen HC; Chen CJ; Van Kriekinge G Value Health; 2012; 15(5):622-31. PubMed ID: 22867770 [TBL] [Abstract][Full Text] [Related]
32. Impact of HPV-16/18 AS04-adjuvanted vaccine on preventing subsequent infection and disease after excision treatment: post-hoc analysis from a randomized controlled trial. Zhao S; Hu S; Xu X; Zhang X; Pan Q; Chen F; Zhao F BMC Infect Dis; 2020 Nov; 20(1):846. PubMed ID: 33198657 [TBL] [Abstract][Full Text] [Related]
33. Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment. Hildesheim A; Gonzalez P; Kreimer AR; Wacholder S; Schussler J; Rodriguez AC; Porras C; Schiffman M; Sidawy M; Schiller JT; Lowy DR; Herrero R; Am J Obstet Gynecol; 2016 Aug; 215(2):212.e1-212.e15. PubMed ID: 26892991 [TBL] [Abstract][Full Text] [Related]
34. Trends in Human Papillomavirus Vaccine Types 16 and 18 in Cervical Precancers, 2008-2014. McClung NM; Gargano JW; Bennett NM; Niccolai LM; Abdullah N; Griffin MR; Park IU; Cleveland AA; Querec TD; Unger ER; Markowitz LE; Cancer Epidemiol Biomarkers Prev; 2019 Mar; 28(3):602-609. PubMed ID: 30792242 [TBL] [Abstract][Full Text] [Related]
35. [In defence of women against HPV-infection]. Blázovics A Orv Hetil; 2007 Apr; 148(17):813. PubMed ID: 17452313 [No Abstract] [Full Text] [Related]
36. The efficacy of HPV 16/18 vaccines on sexually active 18-23 year old women and the impact of HPV vaccination on organized cervical cancer screening. Sigurdsson K; Sigvaldason H; Gudmundsdottir T; Sigurdsson R; Briem H Acta Obstet Gynecol Scand; 2009; 88(1):27-35. PubMed ID: 19031282 [TBL] [Abstract][Full Text] [Related]
37. Success of HPV vaccination is now a matter of coverage. Schiffman M; Wacholder S Lancet Oncol; 2012 Jan; 13(1):10-2. PubMed ID: 22075169 [No Abstract] [Full Text] [Related]
38. Human papillomavirus vaccines versus cervical cancer screening. Stanley M Clin Oncol (R Coll Radiol); 2008 Aug; 20(6):388-94. PubMed ID: 18538554 [TBL] [Abstract][Full Text] [Related]
39. Human papillomavirus vaccine for genotypes 6, 11, 16 and 18: new drug. Cervical cancer prevention: high hopes... Prescrire Int; 2007 Jun; 16(89):91-4. PubMed ID: 17582921 [TBL] [Abstract][Full Text] [Related]
40. Cancers attributable to human papillomavirus infection. Grulich AE; Jin F; Conway EL; Stein AN; Hocking J Sex Health; 2010 Sep; 7(3):244-52. PubMed ID: 20719211 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]